Want to see VVOS full AI Analyst Report?
Top Page
Vivos Therapeutics
(NASDAQ:VVOS)
Select Model
Select Model
Rating:44Neutral
Price Target:
$0.18
▼(-18.18% Downside)
Action:Reiterated
Date:09/06/26
VVOS scores low primarily due to weak financial performance (large losses, negative equity, and sustained cash burn), which drives high financing and solvency risk. Technicals also reflect a strong downtrend, though momentum indicators look oversold. Guidance and operating initiatives are constructive but remain heavily contingent on execution and obtaining additional capital; valuation signals are limited due to negative earnings and no dividend.
Positive Factors
Strong revenue growth
Sustained year-over-year revenue growth indicates expanding patient activity and adoption of Vivos’ diagnostic and treatment services. If maintained, the stronger top line can improve operating leverage, support investment in capacity, and broaden the company’s commercial base over the next several quarters.
Negative Factors
Persistent losses and cash burn
Large operating and net losses show that revenue growth has not yet translated into a self-funding business. Ongoing negative cash generation limits flexibility, increases dependence on external capital, and makes execution of expansion plans more vulnerable to financing delays or unfavorable funding terms.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong revenue growth
Sustained year-over-year revenue growth indicates expanding patient activity and adoption of Vivos’ diagnostic and treatment services. If maintained, the stronger top line can improve operating leverage, support investment in capacity, and broaden the company’s commercial base over the next several quarters.
Read all positive factors
Vivos Therapeutics (VVOS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.75M
Dividend YieldN/A
Average Volume (3M)21.51M
Price to Earnings (P/E)―
Beta (1Y)0.57
Revenue Growth45.21%
EPS Growth-10.29%
CountryUS
Employees268
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-2.06
Shares Outstanding20,118,023
10 Day Avg. Volume58,928,032
30 Day Avg. Volume21,512,289
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)-14.00
Price to Sales (P/S)1.20
P/FCF Ratio-1.18
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$0.75Price Target Upside240.91% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-1.46
Revenue Forecast (FY)$24.06M
Vivos Therapeutics Business Overview & Revenue Model
Company Description
Vivos Therapeutics, Inc. operates as a medical technology company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, ...
How the Company Makes Money
Vivos Therapeutics primarily makes money by selling products and services used by providers to deliver its sleep-disordered breathing treatment approach. Key revenue streams include: (1) revenue from the sale of oral appliance devices and related ...
Vivos Therapeutics Earnings Call Summary
Earnings Call Date:Aug 14, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 18, 2026
Earnings Call Sentiment Negative
The call presented meaningful operational progress: solid revenue growth (Q2 +35%, YTD +51%), improving gross margins, tangible contributions from the Sleep Center of Nevada (sleep testing, treatment), and multiple identified recurring-revenue initiatives (remote monitoring, DME CPAP, EEG/insomnia, pediatric program). However, material financial challenges dominate the risk profile — rising operating losses and cost of sales, heavy cash burn ($9.2M YTD), just $1.8M of cash on hand, substantial doubt about the company’s ability to continue as a going concern, and non-compliance with NASDAQ equity requirements that could trigger delisting. Management’s path to cash-flow positivity by late 2026/early 2027 is plausible but highly execution-dependent and contingent on securing additional financing. Given the severity of near-term liquidity and regulatory (NASDAQ) risks despite operational momentum, the negatives weigh heavily.Positive Updates
Quarterly and Year-to-Date Revenue Growth
Revenue for Q2 2026 was $5.2M, up $1.3M or 35% vs $3.8M in Q2 2025. Revenue for the 6 months ended June 30, 2026 was $10.3M, up $3.5M or 51% vs $6.8M in the prior-year period.
Negative Updates
Decline in Oral Appliance Product Revenue and Unit Revenue Mix
Appliance revenue fell: Q2 appliance revenue ~$1.4M (28% decrease vs prior-year Q2 $1.9M) despite selling more arches (5,180 vs 4,116), driven by a higher mix of lower-priced preformed appliances. For 6 months, arches sold increased to 10,484 but revenue decreased ~24% to $2.8M vs $3.7M prior year.
Read all updates
Q2-2026 Updates
Positive
Negative
Quarterly and Year-to-Date Revenue Growth
Revenue for Q2 2026 was $5.2M, up $1.3M or 35% vs $3.8M in Q2 2025. Revenue for the 6 months ended June 30, 2026 was $10.3M, up $3.5M or 51% vs $6.8M in the prior-year period.
Read all positive updates
Company Guidance
Management guided to a clear path to becoming cash-flow positive near the end of 2026 or in early 2027 and to generating significant positive EBITDA in fiscal 2027, supported by several quantified initiatives: an addressable remote‑patient‑monitoring pool of ~16,000 legacy CPAP patients with an estimated 5,000–7,500 enrollable over 6–12 months at net revenue of $40–$50 per patient per night; a DME CPAP program that, if scaled, could contribute roughly $150,000–$250,000 per month; Henderson capacity expanded to well over $10 million annually; an initial sleep‑optimization team serving ~250 patients/month could yield >$6 million annual revenue with contribution margins of ~40%–50%; cardiology affiliations in Arizona and Florida expected to require $0.8–$1.0 million capex each and begin generating revenue in Q1–Q2 2027—all subject to successful enrollment, reimbursement, vendor economics, payer contracting, staffing and execution (and tempered by the company’s June 30, 2026 cash balance of ~$1.8 million and need for additional financing).Vivos Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
22
Negative
Cash Flow
15
Very Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Dec 2023 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 20.90M | 17.44M | 15.03M | 13.80M | 16.02M | 16.89M |
| Gross Profit | 12.48M | 10.54M | 9.02M | 8.27M | 10.02M | 12.60M |
| EBITDA | -23.25M | -19.92M | -10.55M | -12.96M | -23.18M | -19.54M |
| Net Income | -25.59M | -21.23M | -11.14M | -13.58M | -23.84M | -20.29M |
Balance Sheet | ||||||
| Total Assets | 24.14M | 25.15M | 15.28M | 10.73M | 13.72M | 33.69M |
| Cash, Cash Equivalents and Short-Term Investments | 1.77M | 2.03M | 6.26M | 1.64M | 3.52M | 24.03M |
| Total Debt | 12.14M | 13.50M | 1.51M | 2.00M | 2.41M | 1.63M |
| Total Liabilities | 28.13M | 26.70M | 7.33M | 10.32M | 8.92M | 8.15M |
| Stockholders Equity | -3.81M | -1.49M | 7.95M | 411.00K | 4.80M | 25.54M |
Cash Flow | ||||||
| Free Cash Flow | -17.92M | -17.60M | -13.26M | -12.75M | -20.51M | -18.13M |
| Operating Cash Flow | -17.13M | -15.26M | -12.69M | -11.95M | -19.59M | -15.73M |
| Investing Cash Flow | -1.93M | -7.53M | -568.00K | -853.00K | -924.00K | -2.61M |
| Financing Cash Flow | 16.43M | 18.56M | 17.88M | 10.92M | 0.00 | 24.17M |
Vivos Therapeutics Technical Analysis
Negative
0.22
Price Trends
0.36
Negative
0.54
Negative
1.13
Negative
Market Momentum
-0.05
Positive
30.59
Neutral
6.60
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VVOS, the sentiment is Negative. The current price of 0.22 is below the 20-day moving average (MA) of 0.26, below the 50-day MA of 0.36, and below the 200-day MA of 1.13, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 30.59 is Neutral, neither overbought nor oversold. The STOCH value of 6.60 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VVOS.
Vivos Therapeutics Risk Analysis
Vivos Therapeutics disclosed 53 risk factors in its most recent earnings report. Vivos Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Vivos Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | $3.75M | -0.09 | 2616.82% | ― | 45.21% | -10.29% | |
44 Neutral | $8.28M | -0.04 | -210.99% | ― | -9.18% | 33.16% | |
43 Neutral | $12.30M | -3.35 | -78.94% | ― | 3.68% | 36.91% | |
43 Neutral | $12.53M | -0.42 | -661.85% | ― | -100.00% | 70.33% | |
43 Neutral | $54.95M | -1.06 | 1719.71% | ― | -6.76% | 42.70% |
* Healthcare Sector Average
VVOS
Vivos Therapeutics
0.18
-3.68
-95.36%
IRIX
Iridex
0.68
-0.68
-49.85%
CODX
Co-Diagnostics
1.12
-8.31
-88.12%
ADGM
Adagio Medical Holdings
0.61
-0.87
-58.99%
COCH
Envoy Medical
0.71
-0.57
-44.45%
NXL
Nexalin Technology, Inc.
4.79
-19.59
-80.35%
Vivos Therapeutics Corporate Events
Business Operations and StrategyFinancial Disclosures
Vivos Opens New Henderson Sleep Testing and Treatment Center
Positive
Aug 21, 2026
On August 20, 2026, Vivos Therapeutics announced the grand opening of a new state-of-the-art sleep testing and treatment facility in Henderson, Nevada, under its Sleep Centers of Nevada network, with the official launch set for August 27. The cent...
Business Operations and Strategy
Vivos Therapeutics Strengthens IP for Sleep Apnea Devices
Positive
Aug 11, 2026
On August 5, 2026, Vivos Therapeutics announced the issuance of U.S. Patent No. 12,697,190, a continuation of its 2024 foundational Patent No. 12,048,608 covering its vibrational oral appliance platform with mandibular advancement technology. The ...
Executive/Board Changes
Vivos Therapeutics Appoints New Chief Financial Officer
Neutral
Aug 3, 2026
On July 31, 2026, Vivos Therapeutics’ Chief Financial Officer and Secretary, Bradford Amman, voluntarily resigned from all officer and committee positions, with the company stating the move did not stem from any disagreement over operations,...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Vivos Therapeutics Creates New Series A Preferred Stock
Positive
Jul 7, 2026
On June 30, 2026, Vivos Therapeutics raised approximately $2.1 million through a private investment in public equity, selling 3.61 million units of Series A Convertible Preferred Stock and accompanying warrants to existing investors, including an ...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Vivos Therapeutics Extends Debt-for-Equity Conversion Timeline
Positive
Jun 25, 2026
On June 5, 2026, Vivos Therapeutics entered into a strategic exchange agreement with Streeterville Capital under which a portion of Streeterville’s debt would be exchanged for Vivos preferred and common stock, tied to the company’s equ...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Vivos Therapeutics Plans Rights Offering to Existing Shareholders
Neutral
Jun 16, 2026
On June 11, 2026, Vivos Therapeutics announced plans to file a registration statement with the U.S. Securities and Exchange Commission for a proposed rights offering that would distribute transferable subscription rights to existing shareholders a...
Business Operations and Strategy
Vivos Therapeutics Forms AIM Florida Sleep Care Venture
Positive
Jun 16, 2026
On June 10, 2026, Vivos Therapeutics entered into a collaboration agreement with South Palm Cardiovascular Associates to form AIM Florida, a physician-aligned management services organization focused on sleep apnea and insomnia care for cardiovasc...
Business Operations and StrategyDelistings and Listing ChangesPrivate Placements and FinancingRegulatory Filings and Compliance
Vivos Therapeutics Restructures Debt to Support Nasdaq Compliance
Negative
Jun 8, 2026
Vivos Therapeutics has entered into an exchange agreement with its senior lender Streeterville Capital, under which up to $4.5 million of a secured loan made in June 2025 and used to fund the acquisition of The Sleep Center of Nevada may be conver...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.